What it's for (Indications)
- Insulin lispro and insulin lispro protamine is indicated for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.
- This biphasic insulin formulation provides both rapid-acting insulin lispro to cover postprandial glucose excursions and intermediate-acting insulin lispro protamine to provide basal insulin coverage.
- It is typically prescribed when a pre-mixed insulin regimen is deemed appropriate to achieve target blood glucose levels and reduce HbA1c, simplifying treatment for patients who require both mealtime and basal insulin in a single injection.
- Its use requires careful patient selection and education regarding timing relative to meals to optimize therapeutic outcomes and minimize risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of insulin lispro and insulin lispro protamine must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals, determined by a healthcare professional. It is administered subcutaneously, typically twice daily before breakfast and before dinner. The specific dose and timing relative to meals should be meticulously determined by a healthcare provider experienced in diabetes management. Dose adjustments may be necessary with changes in physical activity, meal patterns, renal or hepatic function, concurrent medications, or during acute illness. Careful and consistent monitoring of blood glucose is essential to optimize dosage, achieve glycemic targets, and minimize the risk of hypoglycemia. Patients should be instructed on proper injection technique and rotation of injection sites to prevent lipodystrophy. |
Safety & Warnings
Common Side Effects
- The most common and clinically significant adverse reaction associated with insulin lispro and insulin lispro protamine, consistent with all insulin products, is hypoglycemia.
- Symptoms of hypoglycemia can range from mild (e.
- g.
- , headache, dizziness, sweating, tremor, hunger, irritability) to severe (e.
- g.
- , seizures, unconsciousness, permanent neurological damage, or death).
- Other common side effects include injection site reactions (e.
- g.
- , pain, redness, itching, swelling at the injection site), lipodystrophy (lipoatrophy or lipohypertrophy) at the injection sites, which can impair insulin absorption, weight gain, peripheral edema, and hypersensitivity reactions (e.
- g.
- , rash, pruritus, urticaria, angioedema, anaphylaxis).
- Rare but serious side effects include severe generalized allergic reactions.
- Regular monitoring for these adverse events and appropriate patient education are crucial for safe use.
Serious Warnings
- Black Box Warning: **Serious Warnings: Hypoglycemia and Medication Errors** All insulin products, including insulin lispro and insulin lispro protamine, can cause severe, life-threatening hypoglycemia. Patients must be thoroughly educated on the symptoms, causes, and appropriate treatment strategies for hypoglycemia. It is imperative that patients closely monitor their blood glucose levels, particularly when initiating therapy, making dosage adjustments, during periods of increased physical activity, dietary changes, or intercurrent illness. Delays in recognizing and treating hypoglycemia can lead to profound complications such as loss of consciousness, seizures, irreversible brain damage, or death. Patients and caregivers should always have access to a rapid source of glucose for emergency treatment. Furthermore, medication errors involving insulin products pose a significant safety risk. Accidental mix-ups between different insulin formulations (e.g., rapid-acting, intermediate-acting, or long-acting insulins, or varying pre-mixed ratios) or concentrations (e.g., U-100 vs. U-200) can result in severe hyperglycemia or hypoglycemia, which can be fatal. Patients and caregivers must be rigorously instructed to always verify the insulin product name, concentration, and type before each and every administration. Insulin pens, cartridges, or syringes must never be shared among patients, even if the needle is changed, due to the critical risk of blood-borne pathogen transmission. Adherence to these strict precautions is fundamental for ensuring patient safety and preventing potentially catastrophic outcomes.
- Hypoglycemia is the most serious and common adverse effect associated with insulin therapy; it can be severe and life-threatening if not promptly treated.
- Patients must be educated on its symptoms, causes, treatment, and prevention.
- Dosage adjustments may be required in patients with renal or hepatic impairment due to altered insulin metabolism and clearance.
- Changes in insulin regimen, strength, manufacturer, type, or method of administration may profoundly affect glycemic control and predispose to hypoglycemia or hyperglycemia, necessitating careful medical supervision and meticulous blood glucose monitoring.
- Co-administration with certain drugs (e.
- g.
- , oral antidiabetic agents, corticosteroids, salicylates, beta-blockers) may significantly alter glucose requirements and require dose adjustments.
- Patients should be advised against sharing insulin pens, needles, or syringes due to the serious risk of pathogen transmission.
- Fluid retention and exacerbation or onset of heart failure can occur with concomitant use of thiazolidinediones (TZDs) and insulin, necessitating careful monitoring for signs and symptoms of heart failure.
How it Works (Mechanism of Action)
Insulin lispro and insulin lispro protamine is a biphasic insulin analog. Insulin lispro is a rapid-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, particularly by skeletal muscle and fat cells, and by inhibiting hepatic glucose production. It exerts its effects by binding to insulin receptors on target cells, thereby facilitating cellular glucose transport and metabolism. Its rapid onset and short duration of action are attributable to its altered amino acid sequence, which prevents hexamer formation upon subcutaneous injection, allowing for faster absorption into the bloodstream. Insulin lispro protamine is an intermediate-acting human insulin analog formed by combining insulin lispro with protamine, which delays its absorption from the subcutaneous tissue and prolongs its duration of action. The combination thus provides both immediate postprandial glucose control and sustained basal insulin activity.